An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss
Proceedings of the National Academy of Sciences · 06.10.2026 · 123 (40)
DOI: 10.1073/pnas.2618845123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 25.09.2026. Verfasst von Anneke K Thorne und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Metabolism, and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago,…. Hauptthemen laut MEDLINE: Thermogenesis, Weight Loss, Oligonucleotides, Antisense, Obesity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHGRI NIH HHS, HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI NIH HHS.
Abstract (Originalsprache)
Current obesity therapies reduce weight but often fail to preserve lean mass or sustain metabolic benefit. Glucagon-like peptide-1 receptor agonists (GLP-1RA) improve obesity-associated metabolic disease, but weight loss is often accompanied by reduced energy expenditure, loss of lean mass, and rapid fat-predominant regain after treatment discontinuation. We hypothesized that pharmacologic activation of adipose thermogenesis could specifically target fat loss, complement appetite suppression by increasing energy expenditure, and improve the metabolic quality of weight loss. Guided by our finding that diet-induced thermogenesis is mediated by a zinc finger protein 423 (ZFP423)-controlled pathway, we developed adipose-directed antisense oligonucleotides (ASOs) targeting ZFP423, a transcriptional repressor of brown and beige adipocyte identity. In lean and diet-induced obese mice, weekly Zfp423 ASO treatment induced white adipose beiging, increased body temperature and oxygen consumption, and improved glucose homeostasis, insulin sensitivity, lipid metabolism, mitochondrial respiration, and hepatic steatosis. When combined with the GLP1-RA semaglutide, Zfp423 ASO produced greater weight and fat loss than either monotherapy while preserving lean mass and improving metabolic outcomes. These findings identify Zfp423 as an RNA therapeutic target and support adipose thermogenesis as a complementary strategy for metabolically healthier obesity treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, Metabolism, and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.
- Center for Genetic Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.
- Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.
- Ionis Pharmaceuticals, Carlsbad, CA 92010.
- Phenome Technologies Inc., Lincolnshire, IL 60091.
- Division of Endocrinology, Department of Medicine, Duke Molecular Physiology Institute, Duke University, Durham, NC 27701.
ORCID-Profile: Anneke K Thorne, Marisa J Stachowski, Ella Simon, Joseph V Mastroni, Pei Zhu, Nicholas J Conley, Andrew B Cohen, Grant D Barish, Lisa R Beutler, Clara B Peek, Elizabeth M McNally, Mark Perelis, Joseph Bass
Förderung
- NHGRI NIH HHS
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NCI NIH HHS
- NIDDK NIH HHS
- NINDS NIH HHS
- NIA NIH HHS
- HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- HHS | NIH | National Institute on Aging (NIA)
Zitieren
APA
Thorne, A. K., Waldeck, N. J., Rose, J. P., Stachowski, M. J., Guak, H., Keeble, A. R., Kuusik, B., Simon, E., Marcheva, B., Mastroni, J. V., Zhu, P., Chong, L. W., Kobayashi, Y., Conley, N. J., Cohen, A. B., Omura, Y., Omura, C., Song, W., Wellems, M., …, & Bass, J. (2026). An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss. Proceedings of the National Academy of Sciences, 123(40). https://doi.org/10.1073/pnas.2618845123
Vancouver
Thorne AK, Waldeck NJ, Rose JP, Stachowski MJ, Guak H, Keeble AR, et al. An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss. Proceedings of the National Academy of Sciences. 2026;123(40). doi:10.1073/pnas.2618845123
BibTeX
@article{Thorne2026,
author = {Thorne, Anneke K and Waldeck, Nathan J and Rose, Jesse P and Stachowski, Marisa J and Guak, Hannah and Keeble, Alexander R and Kuusik, Britta and Simon, Ella and Marcheva, Biliana and Mastroni, Joseph V and Zhu, Pei and Chong, Ling Wa and Kobayashi, Yumiko and Conley, Nicholas J and Cohen, Andrew B and Omura, Yasuhiro and Omura, Chiaki and Song, Weimin and Wellems, Michael and Ramsey, Kathryn M and Barish, Grant D and Beutler, Lisa R and Gupta, Rana K and Peek, Clara B and McNally, Elizabeth M and Hepler, Chelsea and Perelis, Mark and Bass, Joseph},
title = {An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {40},
doi = {10.1073/pnas.2618845123}
}
EUVIMED